The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial

  1. Rodríguez, P.C.
  2. Prada, D.M.
  3. Moreno, E.
  4. Aira, L.E.
  5. Molinero, C.
  6. López, A.M.
  7. Gómez, J.A.
  8. Hernández, I.M.
  9. Martínez, J.P.
  10. Reyes, Y.
  11. Milera, J.M.
  12. Hernández, M.V.
  13. Torres, R.
  14. Avila, Y.
  15. Barrese, Y.
  16. Viada, C.
  17. Montero, E.
  18. Hernández, P.
Zeitschrift:
Clinical and Experimental Immunology

ISSN: 1365-2249,  0009-9104

Datum der Publikation: 2018

Ausgabe: 191

Nummer: 2

Seiten: 229-239

Art: Artikel

DOI: 10.1111/CEI.13061 GOOGLE SCHOLAR lock_openOpen Access editor
Datenquelle: Scopus